Ipilimumab approved for metastatic melanoma

Traynor, Kate
May 2011
American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p768
Academic Journal
The article reports that the Food and Drug Administration (FDA) approved ipilimumab, to be marketed as 'Yervoy' by Bristol-Myers Squibb, for the treatment of metastatic melanoma. It offers information on the product, an immunoglobulin G1&subk; (IgG1&subk;) monoclonal antibody, which binds to the binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Details pertaining to the dosing, immune reactions, warnings and packaging of ipilimumab are also provided.


Related Articles

  • Monoclonal Antibodies for Multiple Myeloma. Helwick, Caroline // Oncology Pharmacist;May2014, Vol. 7 Issue 2, p3 

    No abstract available.

  • FDA actions.  // Clinical Cardiology Alert;Oct2011 Pharmacology, p2 

    The article reports the FDA approval for emticitabibibe/rilpirivine/tenfovir DF for treating HIV-infected patients; brentuximab vedotin, for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma; and vemurafenib for metastatic and unresectable melanoma in patients with BRAF V600E...

  • FDA actions. Elliott, William T. // Critical Care Alert;Oct2011 Supplement, p2 

    No abstract available.

  • Blinatumomab: First Global Approval. Sanford, Mark // Drugs;Feb2015, Vol. 75 Issue 3, p321 

    Blinatumomab (BLINCYTOâ„¢) is a novel, bispecific T-cell engaging antibody that binds cluster of differentiation (CD) 19 antigens on blast cells while also binding and activating the CD3/T cell receptor complex, causing cell lysis. The antibody is being developed by Amgen as a treatment for...

  • Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. Lemech, Charlotte; Infante, Jeffrey; Arkenau, Hendrik-Tobias // Drugs;2013, Vol. 73 Issue 8, p767 

    Previously characterized by a median overall survival of between 6 and 12 months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or...

  • Pembrolizumab: First Global Approval. Poole, Raewyn // Drugs;Oct2014, Vol. 74 Issue 16, p1973 

    Pembrolizumab [Keytruda (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic...

  • CUTANEOUS ONCOLOGY. FDA accelerates approval of melanoma drug. GILLETTE, BILL // Dermatology Times;Feb2015, Vol. 36 Issue 2, p38 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) on the use of the drug nivolumab (Optivo) from Bristol-Myers Squibb for the treatment of melanoma. Topics discussed include details of the latest clinical trial on the drug, an assessment of the results of...

  • FDA Update.  // Oncology Nurse Advisor;Sep/Oct2014, Vol. 5 Issue 5, p15 

    No abstract available.

  • Eribulin approved for advanced breast cancer. Traynor, Kate // American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p6 

    The article reports that Eisai Inc. and the U.S. Food & Drug Administration (FDA) have announced that eribulin mesylate injection can be used for the treatment of metastatic breast cancer. This would be applicable to patients who have previously undergone treatment with an anthracycline and a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics